Accuray Incorporated (ARAY) : Traders are bullish on Accuray Incorporated (ARAY) as it has outperformed the S&P 500 by a margin of 0.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.28%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.9% in the last 1 week, and is up 6.77% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Accuray Incorporated (NASDAQ:ARAY): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.33 and $5.23 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.38. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.36, notching a gain of 0.56% for the day. The total traded volume was 732,676 . The stock had closed at $5.33 on the previous day.
The stock has recorded a 20-day Moving Average of 3.47% and the 50-Day Moving Average is 2.02%. Accuray Incorporated has dropped 12.56% during the last 3-month period . Year-to-Date the stock performance stands at -20.59%.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.